 By Brian Marckx, CFA NASDAQ:NAOV READ THE FULL NAOV RESEARCH REPORT NanoVibronix NASDAQ:NAOV turned in a solid performance in Q2 ending June 30, 2019 on both a financial and operational perspective. Highlights on the financial side include setting record highs on total revenue, PainShield revenue and UroShield revenue, gross margin 78.7 at the widest level for at least the last 14 quarters 